07:13 AM EST, 01/13/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Monday it has placed a $119.5 million investment with Truveta and its affiliated US health operations to advance data collection and analysis across life sciences, public health, and healthcare delivery.

Under the deal, Regeneron said it will also collaborate with Truveta to launch the Truveta Genome Project.

The project will extend Regeneron's DNA sequence-linked healthcare database with a new effort to sequence up to 10 million additional patients, potentially leading to new genetic-based therapies, the company said.

Regeneron's investment is part of Truveta's series C financing round, according to the company. Illumina, a long-standing Regeneron partner, will also invest $20 million in the financing round in support of the Truveta Genome Project, Regeneron added.